Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Pediatric Epilepsy Study in Subjects 1-24 Months

ClinicalTrials.gov ID: NCT00044278

Public ClinicalTrials.gov record NCT00044278. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)

Study identification

NCT ID
NCT00044278
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
197 participants

Conditions and interventions

Conditions

Interventions

  • lamotrigine Drug

Drug

Eligibility (public fields only)

Age range
1 Month to 24 Months
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2000
Primary completion
May 31, 2006
Completion
May 31, 2006
Last update posted
Jan 17, 2017

2000 – 2006

United States locations

U.S. sites
41
U.S. states
21
U.S. cities
39
Facility City State ZIP Site status
GSK Investigational Site Mobile Alabama 36693
GSK Investigational Site Tucson Arizona 85712
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Little Rock Arkansas 72202
GSK Investigational Site Los Angeles California 90027
GSK Investigational Site Los Angeles California 90095
GSK Investigational Site Stanford California 94305-5235
GSK Investigational Site Denver Colorado 80218
GSK Investigational Site Washington D.C. District of Columbia 20010
GSK Investigational Site Jacksonville Florida 32207
GSK Investigational Site Miami Florida 33155-3009
GSK Investigational Site Orlando Florida 32835
GSK Investigational Site Tallahassee Florida 32308
GSK Investigational Site Tampa Florida 33609
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Augusta Georgia 30912
GSK Investigational Site Lexington Kentucky 40536-0284
GSK Investigational Site Saint Paul Minnesota 55102-2383
GSK Investigational Site Columbia Missouri 65211
GSK Investigational Site Kansas City Missouri 64108
GSK Investigational Site Cherry Hill New Jersey 8034
GSK Investigational Site Buffalo New York 14222
GSK Investigational Site Mineola New York 11501
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site Chapel Hill North Carolina 27599
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Akron Ohio 44308-1062
GSK Investigational Site Cleveland Ohio 44106
GSK Investigational Site Columbus Ohio 43205
GSK Investigational Site Portland Oregon 97201-2884
GSK Investigational Site Portland Oregon 97201-2984
GSK Investigational Site Pittsburgh Pennsylvania 15213-2583
GSK Investigational Site Morristown Tennessee 37813
GSK Investigational Site Nashville Tennessee 37212
GSK Investigational Site Dallas Texas 75230
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Salt Lake City Utah 84113
GSK Investigational Site Charlottesville Virginia 22908
GSK Investigational Site Norfolk Virginia 23507
GSK Investigational Site Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00044278, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00044278 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →